(UroToday.com) The 2025 European Association of Urology (EAU) Annual Meeting held in Madrid, Spain was host to the Biomarkers to guide peri-operative management in Uro-oncology Plenary Session. Dr.

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a discussant presentation by Dr. Edwin Posadas discussing two abstracts: “Radical prostatectomy versus ...

(UroToday.com) The 2022 EAU Section of Oncological Urology (ESOU) Annual Meeting included a session on locally advanced and oligometastatic prostate cancer and a presentation by Dr. Mary-Ellen Taplin ...

The treatment of renal cell carcinoma (RCC), a malignancy that is typically chemoresistant, has drastically evolved with the introduction of vascular endothelial growth factor receptor tyrosine kinase ...

Prostate cancer is the most prevalent cancer among men worldwide, and there have been many advances in its diagnosis and treatment. However, critical obstacles remain, including overdiagnosis, high ...

Prostate-specific membrane antigen (PSMA) has been shown to be overexpressed in the neo-vasculature of renal cancers. However, studies investigating the pattern of PSMA expression in primary RCC and ...

Many preclinical hypotheses, including reciprocal feedback activation between AR-PI3K pathway in PTEN loss and ASI-induced "BRCAness" regardless of BRCA1/2 status, have struggled to translate into ...

Dry Mouth Prevention and Management for PSMA Radioligand Therapy "Presentation" - Sue Yom ...

To evaluate the diagnostic performance of a fully automated, commercially available AI algorithm for detecting prostate cancer and classifying lesions according to PI-RADS. In this retrospective ...

Penile squamous cell carcinoma (PSCC) is a rare, aggressive malignancy with a high risk of mortality due to metastasis. A comprehensive understanding of its mutational landscape is critical for ...

To assess the clinical application and efficacy of robotic radical prostatectomy in 50 cases of large-volume (> 100 ml) prostate cancer. A retrospective analysis was conducted on 50 patients with ...

We previously reported outcomes after hypofractionated postprostatectomy radiotherapy (HYPORT) with a median follow-up of 32 months. This was a primary citation supporting the fractionation selection ...